Vandetanib

申請商
賽諾菲股份有限公司 
適應症
無法進行手術切除的局部侵犯或轉移性甲狀腺髓質癌,並且為症狀性及疾病侵襲性的患者(aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease)
含量
300MG
申請商
賽諾菲股份有限公司 
適應症
無法進行手術切除的局部侵犯或轉移性甲狀腺髓質癌,並且為症狀性及疾病侵襲性的患者(aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease)
含量
100MG